Desna Therapeutics

Desna Therapeutics is a preclinical-stage biotechnology company developing antigen-specific tolerizing therapies for autoimmune diseases—an area of rapid growth and significant unmet need. Our proprietary cell-targeted mRNA lipid nanoparticle (LNP) platform leverages the body’s natural immune mechanisms to establish durable, disease-specific tolerance. Backed by strong preclinical data and a leadership team with deep biotech expertise, a history of successful company building, and multiple FDA-approved therapies, Desna is pioneering a new era of immune reprogramming.